The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
look at the buys already to day
trade..buy/sell?......................................
"Further corporate activity remains a real possibility and management has an excellent track record on this front. We envisage deal size in the range of £30-£50m - primarily debt funded."
Chief Executive Officer Chris Spooner said with Sculptra's European launch exceeding expectations and the continued success of Kelo-cote, management have decided to further increase investment in the aesthetics franchise. "In FY14 we expect European growth to accelerate, a continued robust growth rate through our distribution partners in fast-growth emerging markets and a further improvement in group profitability," he said. "With the factory closure complete and all past restructuring and litigation issues now resolved we are confident of a strong improvement in cash flow as the year progresses". Broker N1+ Singer noted that while its top five products moved to 56% of sales, up from 50% last time, and international sales grew 41% at the earnings before interest, tax, depreciation and amortisation (EBITDA) level, "one cannot ignore a weak Europe and UK showing with like-for-like sales at minus-5%". "SPH has delivered an in line set of finals this morning with plenty of evidence validating the strategic direction and acquisition track record," said analyst Sahill Shan, who did not envisage any meaningful change to forecasts.
Profits shot up at dermatology focused drug company Sinclair IS Pharma thanks to strong growth of its aesthetic non-surgical facelift products. Adjusted profit before tax and exceptional items soared 69% to £4.3m on sales up 7.7% to £55.4m. However, exceptional charges of £16.8m, including a £15.2m non-cash impairment charge against intangible assets and goodwill, resulted in a loss before tax of £17m. The company explained that these non-cash charges related to the value of trademarks and goodwill arising from the acquisition of fellow AIM-listed company IS Pharma. Competition from generic drugs for some of IS's branded hospital products over the last year and the prospect of increased competition has resulted in a significant reduction in future sales expectation for both brands resulted in the writedown. The group has sought to refocus its UK sales team away from hospital sales towards aesthetics, where it has made several successful product acquisitions in the past three years: Flamma in 2010, Kelo-cote in 2011 and Sculptra in 2012.
Damn yahoo finance playing up!
I leave work and the sp is 27, get home and it's 24. Ridiculous!
Sinclair Is Pharma (SPH) Director name: Mr Robert Stuart Swanson Amount purchased: 750,000 @ 25.00p Value: £187,500
"We already have a successful distribution partnership with Biocodex in Turkey, which provides the foundation for this new multi-product, multi-country arrangement." Sinclair products which are part of the agreement include: Kelo-cote silicone-gel scar reduction range; Sculptra collagen stimulator for deep tissue regeneration; Papulex for acne; Bio-Taches for hyperpigmentation disorders; Atopiclair for atopic dermatitis; and Sebclair for the treatment of seborrhoeic dermatitis.
Sinclair IS Pharma has signed a 10-year deal with Biocodex to expand its dermatology portfolio in Russia, Turkey and Europe's Benelux countries. Biocodex, an independent French pharmaceutical company, will support in the importation and distribution of Sinclair products to wholesalers. The company will also facilitate in marketing, advertising, and promotion of commodities to clinicians and pharmacies. Sinclair - a London-based pharmaceutical firm focused on treatments in dermatology, wound care and oncology support - expects the new partnership will help the organisation crack new markets. "This partnership with Biocodex supports our growth strategy to create relationships with strong strategic partners and move our product portfolio into fast-growing, emerging markets" Chris Spooner, Chief Executive Officer of Sinclair, said.
Sinclair IS Pharma: Investec raises target from 36p to 40p, keeps buy rating.
buy...wowsa...
The products together generated revenues of €9.1m (around £7.3m) in the year ended December 31st 2011. Annualised EBITDA contribution after investment in selling and promotional costs is expected to exceed £2m. The transaction will be funded through a placing to raise £9m through the issue of 32,142,858 new ordinary shares of 1p each in the Company at 28p per share. This price marks a 4% premium to the closing price on September 28th. The proceeds of the placing will be used to fund the up-front payment, as well as working capital and transaction costs, the firm said. Analysts at Brewin Dolphin said the company's strategic aspiration to build a significant specialty pharmaceutical business had taken a further positive step. "The move further strengthens Sinclair's aesthetic dermatology franchise," they said.
Sinclair IS Pharma said it had secured a long term distribution agreement for three dermatology products. The 100 year deal with Valeant Pharmaceuticals will the see Sinclair making an upfront payment of €9.0m for the rights. The company will make additional sales-based payments over the life of the distribution agreement. Sinclair will be responsible for sales, marketing and distribution of the products in Western Europe with distribution expected to begin at the beginning of December 2012. Chief Executive Chris Spooner said the deal extended Sinclair's dermatology portfolio and enabled it to further leverage the firm's existing sales and marketing infrastructure in the region.
think this may pull back from around this point amd then move on. fib level approx 30p
morning just looking busy with cza at the moment i hope your well mate
morning i think the results were a formality to be honest ive been watching for a while.am keeping an eye on chart for poss breakout.defo one to watch IMO.
HINCTER
ascending triangle chart forming, first target around 32p.results due in september one to watch.
Pharmaceutical firm Sinclair IS Pharma saw a big jump in revenues in the last year driven by international sales. In a trading statement the firm said it expected revenue for the year to the end of June to have grown by 56% to reach £51.3m Like-for-like revenue growth was expected to be 11.3% for the year, it said. Chief Executive Chris Spooner put the strong performance down to a combination of strong growth from international operations, in particular Asia, and more modest like-for-like growth in Europe. "We have continued to improve the growth prospects of our product portfolio by acquisition, and brand extension," he said. "This combined with multiple product launches in Asia, mean that we are well positioned to deliver further growth in the coming year." International operations saw like-for-like growth of 36% for the full year, including growth in Asia of 155% as a result of multiple product launches. The firm said it expected international growth to continue in2013 with several new launches in Asia.
Singer Capital reiterated its "buy" recommendation for Sinclair IS Pharma (SPH) with a target price of 48p. The company has returned the EU rights for its oral mucositis spray Episil, which the broker noted accounted for just 1.5% of sales. As a result, Singer believes the firm will now be able to focus on its core business in mainland Europe of dermatology and woundcare. On the broker's earnings forecasts, the shares trade on a prospective multiple of 20.6 times for the 2012 financial year, falling to 12.4 times in 2013. Shares in Sinclair IS Pharma inched up by 0.125p to 26.75p.
mill trade,loose change me thinks?....
Sinclair IS Pharma, a skin treatments supplier, has amended the terms of the lock-up arrangements with the ex-shareholders of Advanced Bio-Technologies (AB-T), meaning that around 11.478m, or 57%, of the 19.990m shares issued as consideration for the acquisition of AB-T have now been released four months post completion, two months earlier than originally envisaged, with 10,000,000 of these being placed with investors. The remaining 43% will be released on December 15th, as per the original agreement.
Another interesting link: http://www.thehealthage.com/2010/05/new-jab-may-prove-holy-grail-in-curing-cancer/
Here are the links for 'Scancell's Dynamite Revelation.' http://www.express.co.uk/posts/view/175410/Cancer-scientists-hail-huge-leap-towards-jab-that-targets-tumours http://www.dailymail.co.uk/health/article-1278836/Holy-Grail-cancer-vaccine-blasts-tumours-weeks-hailed-huge-leap-fighting-disease.html http://vaccinenewsdaily.com/news/213067-cancer-vaccine-breakthrough-reported/